We describe the design, synthesis, and opioid activity of fluoroalkene (Tyr1-ψ[(Z)CF=CH]-Gly2) and trifluoroethylamine (Tyr1-ψ[(S)/(R)-CF3CH-NH]-Gly2) analogues of the endogenous opioid neuropeptide, Leu-enkephalin. The fluoroalkene peptidomimetic exhibited low nanomolar functional activity (5.0±2 nm and 60±15 nm for δ- and μ-opioid receptors, respectively) with a μ/δ-selectivity ratio that mimics that of the natural peptide. However, the trifluoroethylamine peptidomimetics, irrespective of stereochemistry, did not activate the opioid receptors, which suggest that bulky CF3 substituents are not tolerated at this position.
|Number of pages||6|
|State||Published - Apr 20 2017|
Bibliographical noteFunding Information:
Research reported in this publication was supported by the US National Institute on Drug Abuse under Award Numbers DA036730 (R.A.A.) and DA018151 (T.E.P.), and by the US National Institute of General Medical Sciences under Award Number GM008545 (R.S.C.). Support for the NMR instrumentation was provided by NIH Shared Instrumentation Grant no. S10D016360. We thank Ben Neuenswander for HPLC purifications, and Dr. Victor Day for X-ray crystallography. The content herein is the sole responsibility of the authors and does not necessarily represent the official views of the US National Institutes of Health.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
- amide bonds
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery
- Pharmacology, Toxicology and Pharmaceutics (all)
- Organic Chemistry